Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy
Author:
Publisher
Informa UK Limited
Subject
Oncology
Reference81 articles.
1. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients
2. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma
3. Multiple Myeloma
4. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: myeloma.
5. Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study
Cited by 39 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States;Journal of Managed Care & Specialty Pharmacy;2024-09-09
2. Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy;Hematological Oncology;2024-06-14
3. Current Novel Targeted Therapeutic Strategies in Multiple Myeloma;International Journal of Molecular Sciences;2024-06-04
4. Mathematical Modeling Unveils Optimization Strategies for Targeted Radionuclide Therapy of Blood Cancers;2024-05-23
5. Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma;BMC Cancer;2024-04-29
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3